HIBA-Institutional Registry of Amyloidosis

Amyloidosis Clinical Trial

— RIA-HIBA  

Official title:

Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01347047
• Other study ID #: 1675
• Status: Recruiting
• Start date: April 2011
• Est. completion date: January 2030

Study information

• Verified date: June 2023
• Source: Hospital Italiano de Buenos Aires
• Contact: María L Posadas-Martínez, MD, PhD
• Phone: +54 11 4959 0200
• Email: maria.posadas[@]hospitalitaliano.org.ar
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

1. Creating a population-based registry system Amyloidosis prospective epidemiological survey

• risk factors

• diagnosis

• prognosis

• treatment

• monitoring

• survival

2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires.

3. Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.

Description:

Amyloidosis is a systemic disease that is usually a result of misfolded proteins in the form of amorphous fibrillar material in various tissues and can cause progressive dysfunction of the same. The prevalence of amyloidosis varies depending on the population concerned and the type of amyloid. While prevalence in the general population is unknown, according to estimates by the Mayo Clinic this prevalence is 1 in 90 666% in the U.S. In England this disease generated about 0.0084% (1367 / 16232579) of all hospital visits between April 2008 and April 2009.

The most common clinical manifestations include cardiac disease, renal and liver function, but it may vary widely depending on the type of amyloidosis, the organ infected and extent of the deposits. Amyloid infiltration can produce signs and symptoms that may be very similar to other rheumatic diseases. This may suggest potential clinical polymorphic underdiagnosis due to low clinical suspicion.

The registries are organized systems of systematic data collection of a large number of patients quickly and efficiently on a particular disease at a given time.

The main difficulty of the registries is the guarantee of the quality of their data.

The main objectives of the registry are:

1. Understand risk factors and prognosis.

2. Evaluate the diagnostic and therapeutic comparison with current standards.

3. Advance knowledge of the disease to optimize the assessment, treatment and monitoring of patients.

4. Analyze the effectiveness of new therapies.

5. Studying differences between populations.

6. Quickly estimate the morbidity, mortality and resource utilization associated with a disease entity.

7. Examine the course of a disease

8. Formulate novel hypotheses for further prospective studies. Currently, there are registries for patients with transthyretin amyloidosis (TAHOS), global registry of transplant patients with familial amyloid poly neuropathy. Also, there are indirect registries such as the kidney transplant, heart transplant, among others.

The investigators found no data on the prevalence or incidence, evolution and prognosis of amyloidosis in our country. There are no existing records of national Amyloidosis in Latin America that could describe the behavior of this disease in our environment. Because it is a chronic disease with amyloid infiltration and can produce signs and symptoms that may be very similar to other rheumatic diseases, this clinic potentially poliform, may suggest underestimation of low clinical suspicion. As there is no cure, some patients may persist symptomatic despite adequate therapy, that is why it is important the creation of a monitoring system to generate data on the evolution and prognosis. The data registries can be used to develop new treatment guidelines and recommendations, also to inform and educate physicians on the management of this disease.

The Hospital Italiano de Buenos Aires is a center of high complexity of derivation of this type of pathology and due to the fact that the hospital, that has a private health insurance system (HIBA's health plan [plan de salud, PS], gives the unique opportunity denominators for the generation of a population on their affiliates, therefore the investigators propose to make a Institutional Registry of Amyloidosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 314
• Est. completion date: January 2030
• Est. primary completion date: January 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and/or there is amyloidosis in a biopsy specimen and/or requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis

**Inclusion Criteria: 1 AND (2 or 3)

1. Patients over 18 years:

2. Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)

3. Clinically compatible case of Amyloidosis :

• Exclusion Criteria:

Refusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.

Related Conditions & MeSH terms

• Amyloidosis

Locations

Country	Name	City	State
Argentina	Hospital Italiano de Buenos Aires	Buenos Aires

Sponsors (10)

Lead Sponsor	Collaborator
Hospital Italiano de Buenos Aires	Austral University, Argentina, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno, HOSPITAL BRITANICO DE BUENOS AIRES, Hospital de Alta Complejidad en Red, Hospital de Clinicas José de San Martín, Hospital Privado de Rosario, Instituto Cardiovascular de Buenos Aires, La Fundacion Favaloro para la Investigacion y la Docencia Medica, Sanatorio Anchorena

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epidemiologic characteristics	Survival anual	From inclusion date (daignosis) until the date of death from any cause or date of last follow up(if not dead) assessed up to 10 years
Primary	Epidemiologic characteristics	Organ response	From treatment date until the date of best organ response or documented progression or date of death from any cause, whichever came first, assessed up to 10 years
Primary	From treatment to folow up, annualy	Baseline description	at baseline
Primary	Treatment patterns	Type of treatment, duration, adverse events, completition	From diagnosis, evaluated after every line of treatment or annualy up to 10 years